Impact of an individualized pain plan to treat sickle cell disease vaso-occlusive episodes in the emergency department.

IF 7.4 1区 医学 Q1 HEMATOLOGY Blood advances Pub Date : 2024-10-22 DOI:10.1182/bloodadvances.2023012439
Lauren Siewny, Allison King, Cathy L Melvin, Christopher R Carpenter, Jane S Hankins, Joseph S Colla, Liliana Preiss, Lingzi Luo, Lisa Cox, Marsha Treadwell, Natalia Davila, Rita V Masese, Sarah McCuskee, S Siera Gollan, Paula Tanabe
{"title":"Impact of an individualized pain plan to treat sickle cell disease vaso-occlusive episodes in the emergency department.","authors":"Lauren Siewny, Allison King, Cathy L Melvin, Christopher R Carpenter, Jane S Hankins, Joseph S Colla, Liliana Preiss, Lingzi Luo, Lisa Cox, Marsha Treadwell, Natalia Davila, Rita V Masese, Sarah McCuskee, S Siera Gollan, Paula Tanabe","doi":"10.1182/bloodadvances.2023012439","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>To address acute vaso-occlusive episodes (VOEs), the leading cause of emergency department (ED) visits among individuals with sickle cell disease (SCD), we conducted the clinical study, ALIGN (An Individualized Pain Plan with Patient and Provider Access for Emergency Department care of SCD), across 8 sites. We hypothesized an improvement of 0.5 standard deviations in perceived quality of ED pain treatment of a VOE after implementing individualized pain plans (IPPs) accessible to both patients and providers. Patients with SCD were aged 18 to 45 years, owned a cell phone, and had an ED VOE visit within 90 days prior. Patients completed the perceived quality of care surveys at baseline and within 96 hours after an ED VOE visit. Providers completed surveys regarding comfort managing VOEs at baseline and after managing an enrolled patient. Most of the 153 patients were African American (95.4%), female (64.7%), and had Hb SS/Sβ0 genotype (71.9%). The perceived quality of ED pain treatment was high at both baseline and after implementation of IPPs; our primary outcome hypothesis was not met, because no statistically significant change in the patient-perceived quality of ED treatment occurred. A total of 135 providers completed baseline and follow-up surveys. On a scale of 1 to 7, with 7 being extremely comfortable managing VOEs, 60.5% reported a score ≥6 after IPP implementation vs 57.8% at baseline. Almost all (97.6%) ordered the recommended medication, and 94.7% intended to use IPPs. In this implementation protocol, all sites successfully implemented IPPs. Patients and ED providers both endorsed the use of IPPs. This trial was registered at www.ClinicalTrials.gov as # NCT04584528.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":null,"pages":null},"PeriodicalIF":7.4000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood advances","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/bloodadvances.2023012439","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: To address acute vaso-occlusive episodes (VOEs), the leading cause of emergency department (ED) visits among individuals with sickle cell disease (SCD), we conducted the clinical study, ALIGN (An Individualized Pain Plan with Patient and Provider Access for Emergency Department care of SCD), across 8 sites. We hypothesized an improvement of 0.5 standard deviations in perceived quality of ED pain treatment of a VOE after implementing individualized pain plans (IPPs) accessible to both patients and providers. Patients with SCD were aged 18 to 45 years, owned a cell phone, and had an ED VOE visit within 90 days prior. Patients completed the perceived quality of care surveys at baseline and within 96 hours after an ED VOE visit. Providers completed surveys regarding comfort managing VOEs at baseline and after managing an enrolled patient. Most of the 153 patients were African American (95.4%), female (64.7%), and had Hb SS/Sβ0 genotype (71.9%). The perceived quality of ED pain treatment was high at both baseline and after implementation of IPPs; our primary outcome hypothesis was not met, because no statistically significant change in the patient-perceived quality of ED treatment occurred. A total of 135 providers completed baseline and follow-up surveys. On a scale of 1 to 7, with 7 being extremely comfortable managing VOEs, 60.5% reported a score ≥6 after IPP implementation vs 57.8% at baseline. Almost all (97.6%) ordered the recommended medication, and 94.7% intended to use IPPs. In this implementation protocol, all sites successfully implemented IPPs. Patients and ED providers both endorsed the use of IPPs. This trial was registered at www.ClinicalTrials.gov as # NCT04584528.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在急诊科治疗镰状细胞病血管闭塞性发作的个性化疼痛计划的影响。
急性血管闭塞症(VOE)是镰状细胞病(SCD)患者到急诊科(ED)就诊的主要原因,为了解决这一问题,我们在八个医疗点开展了一项临床研究,名为 "镰状细胞病急诊科患者和医护人员可参与的个性化疼痛计划"(ALIGN)。我们假设,在实施患者和医疗服务提供者均可参与的个性化疼痛计划(IPPs)后,VOE 对急诊室疼痛治疗质量的感知将提高 0.5 个标准差。SCD 患者年龄在 18-45 岁之间,拥有一部手机,90 天内曾在急诊室就诊过一次。患者在基线期和就诊后 96 小时内完成了护理质量感知调查。医疗服务提供者在基线和管理注册患者后完成了有关管理 VOE 舒适度的调查。153 名患者中,大多数为非洲裔美国人(95.4%)、女性(64.7%)和 Hb SS/Sβ0 基因型患者(71.9%)。在基线和实施 IPP 后,患者对 ED 疼痛治疗质量的感知都很高;由于患者对 ED 治疗质量的感知没有发生统计学意义上的显著变化,因此我们的主要结果假设没有实现。共有 135 名医疗服务提供者完成了基线和后续调查。在 1-7 分的量表中,7 分表示在管理 VOE 方面非常得心应手,实施 IPP 后,60.5% 的医疗服务提供者的得分≥6 分,而基线时为 57.8%。几乎所有人(97.6%)都订购了推荐药物,94.7%的人打算使用 IPP。在该实施方案中,所有地点都成功实施了 IPP。患者和急诊室医护人员都认可使用 IPP。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Blood advances
Blood advances Medicine-Hematology
CiteScore
12.70
自引率
2.70%
发文量
840
期刊介绍: Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016. Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.
期刊最新文献
Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice. A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Antithrombotic efficacy and bleeding risks of vaccine-induced immune thrombotic thrombocytopenia treatments. In vivo silencing of intestinal DMT1 mitigates iron loading in β-thalassemia intermedia (Hbbth3/+) mice. Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1